| Date | Title | Description |
| 27.03.2024 | Erasca Announces $45 Million Oversubscribed Private Placement Financing | - |
| 12.07.2021 | Erasca, Inc. Prices IPO | Erasca, Inc. announced the initial public offering of 17,500,000 shares of its common stock on July 12. The common stock will be priced between $14.00 and $16.00 per share, according to Erasca’s Form S-1/A.
Erasca, Inc. was founded in 2018 ... |
| 01.09.2020 | Erasca raises an additional $36 million in Series B funding round to treat and erase cancer | Erasca, a San Diego, Californa-based biotech startup that has its mission embedded in its name (erase cancer), today announced it has closed an additional $36 million of its Series B funding round to finance the clinical development of mult... |
| 01.09.2020 | Erasca Completes $36M Extension of Series B Financing | Erasca, a San Diego, CA-based cancer therapeutics company, completed a $36m extension of its Series B financing round, which brings the total round to $236m.
This financing brings the total capital raised by the company to $300m. New invest... |
| 31.08.2020 | Erasca Brings In $36M More For Series B For Cancer Treatments | 12 Shares Email Facebook Twitter LinkedIn
Erasca, creating oncology drugs intended to provide precision oncology options, closed on an additional $36 million to bring its Series B financing round to a total of $236 million, the company said... |
| 31.08.2020 | Erasca has announced raising an additional $36M, bringing its total Series B funding to $236M | - |
| 31.08.2020 | Erasca : Extends Series B Financing to $236 Million | Erasca, a company whose mission is to erase cancer, today announced the completion of a $36 million extension of its Series B financing round, which brings the total round to $236 million. New investors include Partner Fund Management and O... |
| 31.08.2020 |
Erasca Bumps Series B To $236M
| San Diego-based cancer treatment developer Erasca announced Monday that it has completed a $36M extension to its Series B funding round, bringing that funding to $236M in total. The new funding came from such investors as Partner Fund Manag... |
| 31.08.2020 | Erasca Extends Series B Financing to $236 Million | SAN DIEGO--(BUSINESS WIRE)--Erasca, a company whose mission is to erase cancer, today announced the completion of a $36 million extension of its Series B financing round, which brings the total round to $236 million. New investors include P... |
| 31.08.2020 | Erasca Snares $36M Series B Extension |
SAN DIEGO, CA, Erasca announced the completion of a $36 million extension of its Series B financing round.
>> Click here for more funding data on Erasca
>> To export Erasca funding data to PDF and Excel, click here
Erasca... |
| 31.08.2020 | Erasca Brings In $36M More For Series B For Cancer Treatments | 11 Shares Email Facebook Twitter LinkedIn
Erasca, creating oncology drugs intended to provide precision oncology options, closed on an additional $36 million to bring its Series B financing round to a total of $236 million, the company said... |
| 31.08.2020 | Erasca Extends Series B Financing to $236 Million | SAN DIEGO--(BUSINESS WIRE)--Erasca, a company whose mission is to erase cancer, today announced the completion of a $36 million extension of its Series B financing round, which brings the total round to $236 million. New investors include P... |
| 12.05.2020 | Erasca Raises $200 Million in Series B Via a Virtual Roadshow | Erasca, a biotech company with a bold goal of “erasing cancer,” showed some of that determination when it recently completed a $200 million Series B funding round under less than ideal conditions...
Take 1 minute to subscribe and you'll get... |
| 27.04.2020 | Singapore’s EDBI joins US oncology startup Erasca’s $200m Series B round | Premium
US-based cancer-treatment startup Erasca has raised $200 million in its Series B round led by ARCH Venture Partners and Cormorant Asset Management, the company said in a statement Monday.
Continue reading this story with a subscript... |
| 27.04.2020 | Biotech startup Erasca raises $200 million Series B funding to fight cancer | Erasca, a San Diego, California-based biotech startup on a mission to eradicate cancer, today announced the completion of a $200 million Series B funding to support the clinical development of multiple promising oncology programs and furthe... |
| 27.04.2020 | Erasca Raises $200 Million Series B Financing | - |
| 27.04.2020 | Erasca Raises $200M Series B Financing |
SAN DIEGO, CA, Erasca announced the completion of a $200M Series B financing round co-led by ARCH Venture Partners and Cormorant Asset Management.
>> Click here for more funding data on Erasca
>> To export Erasca funding dat... |
| 27.04.2020 | Erasca Raises $200M in Series B Financing | Erasca, a San Diego, CA-based develper of oncology programs, completed a $200m Series B financing round.
The round, which brought the total capital raised to more than $260m, was co-led by Arch Venture Partners and Cormorant Asset Managemen... |
| 27.04.2020 | Erasca Raises $200 Million Series B Financing | SAN DIEGO--(BUSINESS WIRE)--Erasca, a company whose mission is to erase cancer, today announced the completion of a $200 million Series B financing round co-led by ARCH Venture Partners and Cormorant Asset Management. New investors particip... |
| 27.04.2020 | Erasca Raises $200 Million To Combat Cancer | Erasca, a company on a mission to erase cancer, announced the completion of a $200 million Series B financing round co-led by ARCH Venture Partners and Cormorant Asset Management
Erasca — a company that is on a mission to erase cancer — ann... |
| 27.04.2020 | Erasca has secured $200M in Series B financing in a quest to cure cancer | - |
| 06.03.2019 | Term Sheet — Wednesday, March 6 | BAD MEDICINE
Medicine and money can be a dangerous combination. The rapid rise of health system venture capital funding is surfacing some thorny ethical dilemmas, according to a Healthcare Dive investigation.
Paid Content You can't secure w... |
| 06.03.2019 | San Diego-Based Erasca Raises $64 Million To Create New Generation Of Oncology Drugs | Erasca, a San Diego-based company that is dedicated to advancing scientific approaches for erasing cancer, has closed a Series A extension bringing the total to $64 million. New investors in this round include ARCH Venture Partners, Andrees... |
| 05.03.2019 |
Erasca Raises $64M For Oncology Drug Development Using AI
| San Diego-based Erasca, a company which is using artificial intelligence to drive the discovery and development of new oncology drugs to help cure cancer, has raised $64M in a Series A funding, the company said this morning. The funding--wh... |
| 05.03.2019 | Erasca Raises Series A Extension; Round Totals $64M | Erasca, a San Diego, CA-based developer of new scientific approaches to erase cancer, closed an extension to its Series A financing round, bringing the total raised to $64m.
Backers included:
– Arch Venture Partners,
– Andreessen Horowitz,
... |
| 05.03.2019 | Pfizer stokes rumor mill with plan to raise $5B in debt; Lilly's CGRP Emgality wins speedy review for cluster headaches | → Pfizer $PFE is raising $5 billion in debt, and in this heated M&A environment, there’s quite a bit of buzz about what the money will be spent on. For the record, their statement says it will be used for general corporate ... |
| 19.12.2018 | San Diego-Based Erasca Raises $42 Million To Target Biological Drivers Of Cancer | Erasca, a San Diego, California-based company, has raised $42 million in Series A funding co-led by founding investors City Hill Ventures and Cormorant Asset Management. Additional institutional and individual investors also participated in... |
| 18.12.2018 | Erasca launches with $42M in Series A funding with ‘erasing cancer’ as its goal | To be sure, with oncologists usually careful to use the c-word for patients only in specific instances – disease-free for a certain number of years and expected to remain alive for as long as if there were no cancer – that’s a big ask. But ... |
| 18.12.2018 | Erasca picks up $42M to target biological drivers of cancer | Erasca has raised a $42 million series A round from the likes of City Hill Ventures and Cormorant Asset Management to work toward the lofty goal to “not just treat, but actually cure cancer.”
Sponsored by Agilent Technologies
How would you ... |
| 18.12.2018 | Erasca picks up $42M to target biological drivers of cancer | Erasca has raised a $42 million series A round from the likes of City Hill Ventures and Cormorant Asset Management to work toward the lofty goal to “not just treat, but actually cure cancer.”
That’s right—they used the “c” word.
The company... |
| 18.12.2018 | Erasca Raises $42M in Series A Financing | Erasca, a San Diego, CA-based company dedicated to advancing scientific approaches to erase cancer, completed a $42m Series A financing.
The round was co-led by City Hill Ventures and Cormorant Asset Management, with participation from inst... |
| 18.12.2018 |
Erasca Picks Up $42M For Cancer Drugs
| San Diego-based Erasca, a biopharmaceuticals startup which says it intends to develop oncology drugs to not just treat, but cure, cancer, has raised $42M in a Series A funding round. The funding was led by City Hill Ventures and Cormorant A... |
| 18.12.2018 | Term Sheet — Tuesday, December 18 | A DECEMBER SLUMP
Good morning, Term Sheet readers.
Paid Content Securing the enterprise without boundaries From ExtraHop
Markets are bracing themselves for rough days ahead. As the market continues to plunge, the Dow Jones Industrial Averag... |
| - | Erasca launches with $42M in Series A funding with ‘erasing cancer’ as its goal | An oncology-focused pharmaceutical startup launched Tuesday is the latest to emerge directly from the venture capital world.
Erasca, based in San Diego, announced its launch with a $42 million Series A funding round, co-led by City Hill Ven... |
